BioSpace News Archive

Great Place to Work Institute has honored Watercrest Senior Living Group with official certification as a Great Place to Work®, evaluating over 1,000 employee surveys from across Watercrest’s multiple locations.

Children who are removed from their parents’ care by the child welfare system because of substance use and put in foster care are now more likely to be placed with relatives than non-relatives according to a newly updated report from Generations United- Raising the Children of the Opioid Epidemic: Solutions and Support for Grandfamilies.

Physicians’ Education Resource® (PER®), the leading provider of oncology and hematology continuing medical education (CME), announces the full agenda for the 2018 New York Cardio-Endo-Renal Collaborative (NY CERC).

Enzychem Lifesciences, Corporation (KOSDAQ:18930), a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, today announced the successful completion of a two-day investor roadshow in Singapore and Hong Kong from September 4 to 5, 2018,

Lakeside Community Healthcare (LCH) is working to make flu vaccinations an in-and-out process by offering appointment-free walk-in and drive-thru flu shot clinics in 5 cities throughout Los Angeles and Ventura Counties. Doctors and trained medical staff will be on-site to administer the shots, ensuring a quick and easy experience.

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York.

Quantum Leap Healthcare Collaborative™ (QLHC) announced today that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL™ includes the study of olaparib and durvalumab, two agents from AstraZeneca.

he Government of Canada is taking major steps to improve health outcomes and access to health services for First Nations through health transformation investments in First Nation communities across Canada.

Gilead Sciences, Inc.and Galapagos NV today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS).

Today, Driver, a global technology platform that connects cancer patients to the best treatments, launches in the United States and China.